Updates
Cures For Hair Loss 2023
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
Amplifica Eyes Trial This Year 2023
A new writeup which was featured on the UC Irvine News website titled "Huting for cures to hair loss" detailed the works of Dr. Maksim Plikus, a research scientist, and Dr. Natasha Mesinkovska, a dermatologist and research scientist. Dr. Plikus is well known for his work studying hairy moles which appear on human skin and for his co-founding of the biotech company Amplifica. Notably, theUCI articlementions that "Human trials on the company’s lead compound are expected to begin later this year." The company mentioned, of course, being Amplifica.
Kintor Completes Enrollment For Phase 3 Trial in China
Announced today through a company press release, Kintor has completed enrollment of 740 male subjects in its phase 3 trial of pyrilutamide aka KX-826 for the treatment of androgenic alopecia. This means that the latest subjects to enter the trial still need to complete their 24 weeks of dosing of the drug or placebo depending on which they received. Kintor is hopeful that pivotal data from this important phase 3 trial will readout later this year in Q4 2023. The company also announced intoday's releasethat the US phase 2 trial for male AGA is expected to readout its data in Q2 2023.
OliX Pharmaceuticals Receives Approval For Phase 1 Trial & Plans Cosmeceutical
OliX Pharmaceuticals of Korea announced today the approval from a regulatory committee in Australia to begin a phase 1 clinical trial for OLX72021, the new development name of its therapy for androgenic alopecia. The planned trial will be a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose phase 1 study, according totoday's release. Perhaps even more interesting, OliX's founder Dr. Dong Ki Lee stated that the company also plans to develop a cosmeceutical version of OLX72021 after safety is confirmed in the upcoming phase 1 trial. This would make the second androgen receptor siRNA cosmeceutical on the horizon after the the popular CosmeRNA which intends to launch soon.
Rion Trialing Topical Exosome Product
Rion Aesthetics, a branch of the Rion Therapeutics company, is trialing a topical exosome-based hair growth product, according to itswebsite. Last June, Follicle Thought published anarticlefeaturing Rion and other exosome companies who are delving into hair loss therapies. Since then, the information about Rion's work in hair growth has shifted to the Rion Aesthetics website. I reached out to Rion Aesthetics who told me that they are seeking to release a topical "cosmetic" product for scalp/hair health later this year in 2023. They also mentioned potentially initiating a FDA clinical trial for an injectable version of their exosome product for hair growth later this year.
Rion Aesthetics currently sells a topical exosome-derived product for skincare calledplated. If their exosome product for hair growth pans out it could provide an option for those who avoid drug-based topicals, and could also bolster regimens which include them. Note that the pricing of Rion's first skincare product is quite premium.
Follicum & HairClone推出新网站
Two companies who have faced challenges along their way to bring a new and effective hair growth treatment to market, Follicum and HairClone, have both recently launched new websites.
Follicum is now seeking to enter a new phase 2b trial to reestablish the potential of its candidate molecule FOL005 as a treatment for androgenic alopecia in both men and women. Last year after the company was acquired by Coegin, CEO Kristian Lykke Fick presented data claiming that after a further evaluation of FOL005's most recent clinical trial which halted the company, there is merit to its effectiveness and the drug should be investigated further.Follicum's websitehas been updated and for the first time discusses FOL005's effect as a nueropilin-1 (NRP-1) receptor agonist.
HairClone of the UK recently had their logo redesigned along withtheir website. I guess it is the season for new websites. The fresh look may be part of a new initiative for HairClone to attract investment for their potentially advantageous business model which includes providing expanded DP cell treatments to physicians in the UK before entering typical clinical trials. There is still no solid start date announced for these treatments.
The Booming Business Of Hair Loss
In January 2023, a new review on the hair growth treatment industry was published inTrends in Biotechnologycalled "The booming business of hair loss." The peer-reviewedarticledetails many of the latest and greatest attempts to develop new effective clinical therapies against hair loss. Many well known companies like Hope Medicine, Stemson Therapeutics, CosmeRNA, and others are described in the review. I was surprised to find that FollicleThought.com was listed as a "Resource" by the authors who wrote the article. This is a first for this site and a gratifying achievement.
New Site Layout
As you can see, the Follicle Thought website is getting an overhaul. Over the next 48 hours all of the kinks should be worked out and the older Updates will begin to replenish. Thanks for reading.
Cutia Therapeutics Launches Website
One of the latest companies to enter a phase 1 clinical trial for AGA, Cutia Therapeutics of China, has officially launched its website. The company currently shows 6 programs for alopecia in itspipeline, one of them being a new chemical entity, CU-40101, which is described as a topical small molecule thyroid hormone receptor agonist.
CosmeRNA Coming Soon?
A Korean news article published today announced that CosmeRNA has been registered as a cosmetic product in the UK and EU. These registrations allow CosmeRNA to be sold as a functional cosmetic and could mean that sales of the product are imminent. Stay tuned for moreannouncements.
Amplifica Makes SCUBE3 Official
传入的消息应用毛发生长/损失t industry seems to be rolling in at an all-time high these days. Just two weeks after announcing their collaboration with UK biotech Ingenza, Amplifica has issued anotherpress releaseannouncing that they have officially added SCUBE3 to their development pipeline. In order to do so, Amplifica signed a license agreement with the University of California, where the original hair follicle signaling research took place. The SCUBE3 product will be labeled as AMP-601 in the company’s pipeline.